CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Other BCL6 small molecule inhibitors, 79-6 (Cerchietti et al., 2010) and FX1 (Cardenas et al., 2016) have also been developed, and FX1 in combination with TKI significantly decreased colony-forming capacity of CML CD34+ cells (Madapura et al., 2017).